Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
25.2M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
4.28M
-
Shares change
-
+2.19M
-
Total reported value, excl. options
-
$4.23M
-
Value change
-
+$1.97M
-
Put/Call ratio
-
0.01
-
Number of buys
-
19
-
Number of sells
-
-12
-
Price
-
$0.99
Significant Holders of Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) as of Q1 2024
51 filings reported holding AXDX - Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share as of Q1 2024.
Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.28M shares
of 25.2M outstanding shares and own 16.95% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (1.85M shares), GRIFFIN ASSET MANAGEMENT, INC. (1.35M shares), VANGUARD GROUP INC (315K shares), GEODE CAPITAL MANAGEMENT, LLC (131K shares), Cannell & Spears LLC (115K shares), Alyeska Investment Group, L.P. (80.5K shares), NORTHERN TRUST CORP (62.7K shares), TCI Wealth Advisors, Inc. (58.7K shares), BlackRock Inc. (50.8K shares), and ORACLE INVESTMENT MANAGEMENT INC (42.1K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.